StoxQ-Line Biotech Limited
NSE: QLINE · Unclassified
Ask the data
Instant answers about Q-Line Biotech Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY26 | |
|---|---|
| Revenue | 341.7 |
| EBITDA | 98.0 |
| Operating margin | 28.7% |
| Interest | 19.4 |
| Depreciation | 10.8 |
| Profit before tax | 72.5 |
| Tax | 16.8 |
| Net profit | 55.7 |
| EPS ₹ | 34.79 |
| Operating cash flow | 16.4 |
| Capex | 35.9 |
| Dividend paid | 0.0 |
| Total assets | 558.7 |
| Equity | 246.2 |
Half-yearly performance
last 2 half years · ₹ crore| H1 FY26* | H2 FY26 | |
|---|---|---|
| Revenue | 143.8 | 197.9 |
| Operating profit | 36.0 | 62.1 |
| Operating margin | 25.0% | 31.4% |
| Other income | 2.7 | 3.0 |
| Interest | 8.3 | 11.1 |
| Depreciation | 4.1 | 6.7 |
| Profit before tax | 26.2 | 46.3 |
| Tax | 4.9 | 11.9 |
| Net profit | 21.3 | 34.4 |
| EPS ₹ | 13.31 | 21.48 |
Returns & margins
trailing-twelve-month, per half year| H2 FY26 | |
|---|---|
| ROE | 22.6% |
| ROCE | 19.5% |
| Net margin | 16.3% |
| EBITDA margin | 28.7% |
| Debt / equity | 0.92 |
| Interest coverage | 4.74 |
| Asset turnover | 0.61 |
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '26 | |
|---|---|
| Share capital | 16.3 |
| Other equity / reserves | 229.9 |
| Total equity | 246.2 |
| Borrowings | 225.5 |
| Current liabilities | 209.9 |
| Non-current liabilities | 102.6 |
| Total assets | 558.7 |
| Property, plant & equipment | 118.6 |
| Investments | 16.7 |
| Inventories | 95.0 |
| Receivables | 125.8 |
| Cash & equivalents | 41.2 |
Cash flow
annual · ₹ crore · line = free cash flow| FY26 | |
|---|---|
| Cash from operations | 16.4 |
| Cash from investing | -29.4 |
| Cash from financing | 41.6 |
| Capex | 35.9 |
| Free cash flow | -19.5 |
| Dividends paid | 0.0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Q-Line Biotech Limited | 833 | 511.70 | 14.9 | 3.38 | 22.6% |
StoxGud checklist: Neutral setup · 4/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Q-Line Biotech Limited?
Q-Line Biotech Limited (QLINE) closed at ₹511.70 on NSE on 06 Nov 2026.
What is the market cap of Q-Line Biotech Limited?
₹833 crore at the latest close.
What is the P/E ratio of Q-Line Biotech Limited?
14.9, on trailing-twelve-month earnings from its filings.
How fast is Q-Line Biotech Limited growing?
Not enough filed history yet to measure Q-Line Biotech Limited's growth.
How profitable is Q-Line Biotech Limited?
On a trailing-twelve-month basis return on equity is 22.6%, return on capital employed 19.5%, operating margin 28.7%, net margin 16.3%.
How much debt does Q-Line Biotech Limited have?
Q-Line Biotech Limited is moderately geared: debt to equity is 0.92 with borrowings of ₹225 cr against cash of ₹41 cr (balance sheet of 2026-03-31). Operating profit covers interest 4.7 times.
Financials parsed from Q-Line Biotech Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Half-yearly from H1 FY26, annual from FY26, balance sheet from Mar '26. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.